ABSTRACT Fluorescence detection of early lung cancer (carcinoma in situ/microinvasive cancer) using Photofrin (porfimer sodium) has been limited by the complexity of the equipment required as well as the prolonged skin photosensitivity associated with high doses of photofrin. A new imaging system is described that can detect dysplasia and carcinoma in situ using differences in tissue autofluorescence. A clinical prototype has been developed consisting of a helium-cadmium laser, an image-intensified CCD camera with filters, an image processing system and a video monitor. The same device can also be used with low non-skin toxic doses of Photofrin when necessary.
Buy this Article
|